| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 13 May 2025 | 17 Apr 2025 |
| Glaxosmithkline Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2025 inter alia to consider and approve As per attachment Outcome of Meeting The Board has recommended a final dividend of Rs.42/- per equity share on face value of Rs .10 each for the year ended 31 st March 2025, subject to approval of members at 100th Annual General Meeting (As Per BSE Announcement Dated on :13.05.2025) | ||
| Board Meeting | 26 Mar 2025 | 26 Mar 2025 |
| outcome of Meeting | ||
| Board Meeting | 14 Feb 2025 | 15 Jan 2025 |
| GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2025 inter alia to consider and approve Un Audited financial results for quarter and nine months ended 31st December 2024 Further to letter dated 15th January 2025, relating to intimation of Board Meeting scheduled to be held on Monday, 10th February 2025 the Board meeting is rescheduled on Friday, 14th February 2025 inter-alia, to approve and take on record the Un-audited financial results for the third quarter & nine months ended 31st December 2024. As per attachment (As per BSE Announcement Dated on 20/01/2025) outcome attachment Revsied outcome of meeting (As Per BSE Announcement Dated on 14.02.2025) | ||
| Board Meeting | 29 Oct 2024 | 24 Oct 2024 |
| GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2024 inter alia to consider and approve Unaudited Financial Results for quarter & half year ended 30th September 2024 and to consider the declaration of interim dividend (if any) Outcome of Meeting The Board has recommended Special Interim dividend of Rs. 12/- (120%) per equity share on face value of Rs.10 each of the Company. (As Per BSE Announcement Dated on 29.10.2024) | ||
| Board Meeting | 2 Aug 2024 | 17 Jul 2024 |
| GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/08/2024 inter alia to consider and approve Un-Audited Financial Results for the first quarter ended 30th June 2024 Outcome of meeting (As Per BSE Announcement dated on 02.08.2024) | ||
Here are some of the stocks that may see significant price movement today: GIC Re, GSK Pharma, Godfrey Philips, etc.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
